title: [Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].
abstract: BACKGROUND
  New drugs have recently been developed, through a better understanding of the mechanisms involved in the progression of prostate cancer, including castration-resistant ones (CRPC). This article aims to describe the mechanisms of action of these new hormonal treatments and their major clinical outcomes and development programs.
  
  
  METHODS
  A bibliographic research in French and English using Medline(®) and Embase(®) using the keywords "castration-resistant prostate cancer", "abiraterone acetate", "orteronel", "enzalutamide", and "clinical trials" was performed.
  
  
  RESULTS
  the androgen signaling pathway remains the cornerstone of advanced cancers management. Hence, some molecules target the androgen biosynthesis, as abiraterone acetate and orteronel, which are selective inhibitors of the enzyme CYP17. Others act as antagonists of the androgen receptor: the enzalutamide, RNA-509 and ODM201. Finally, galeterone combines the two effects.
  
  
  CONCLUSIONS
  Progress conferred by these molecules in terms of overall survival and quality of life in patients with metastatic CRPC, suggest that their use at earlier stages of the disease could reduce morbidity and mortality from prostate cancer. Determining the best strategy for sequence or combination therapy to optimize the use of these new molecules should be investigated.
authors: Service d'urologie, hôpital Foch, université de Versailles - Saint-Quentin-en-Yvelines (UVSQ), 92150 Suresnes, France. Electronic address: yann.neuzillet@gmail.com.
authors: Y
authors: Y
authors: Neuzillet
authors: V
authors: V
authors: Flamand
authors: S
authors: S
authors: Lebdai
authors: A
authors: A
authors: Villers
authors: T
authors: T
authors: Lebret
mesh_terms: D000069501:Abiraterone Acetate; D000726:Androgen Antagonists / Q000627:therapeutic use*; D059002:Androgen Receptor Antagonists / Q000627:therapeutic use; D000730:Androstadienes / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001549:Benzamides; D002986:Clinical Trials as Topic; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008297:Male; D009281:Naphthalenes / Q000627:therapeutic use; D009367:Neoplasm Staging; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011788:Quality of Life; D013254:Steroid 17-alpha-Hydroxylase / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D059002:Androgen Receptor Antagonists; D000730:Androstadienes; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D001549:Benzamides; D007093:Imidazoles; D009281:Naphthalenes; D009570:Nitriles; D010669:Phenylthiohydantoin; C540278:enzalutamide; D013254:Steroid 17-alpha-Hydroxylase; D000069501:Abiraterone Acetate; C571806:orteronel
keywords: Abiraterone acetate; Acétate d’abiratérone; Cancer de prostate résistant à la castration; Castration-resistant prostate cancer; Clinical trials; Enzalutamide; Essais cliniques; Galeterone; Galétérone; ODM201; Orteronel; Ortéronel; RNA-509